OCF fell 76.4% on a 3.0% revenue dip; 13c dividend funded by UK share sale

NPAT from continuing operations fell 12.9% to $29.0m, with a flat 28.2% effective tax rate ruling out any tax distortion.

Capex rose 63.7% to $15.7m, lifting capex intensity to 9.1% of revenue from 5.4%. Combined with the weaker operating inflow, free cash flow pre-lease swung to -$12.3m from +$4.7m. Cash on hand fell to $38.3m from $45.3m; the balance sheet remains debt-free.

The board declared a 13c per share special dividend explicitly sourced from proceeds of selling LIC's UK shareholding, not from underlying operations.

Operating cash flow of $3.4m represents just 11.6% of NPAT, against 42.9% in the prior comparable. The 76.4% drop in OCF on a 3% revenue decline points to working capital absorption that is not visible in the P&L: trade debtors stand at $86.7m, equivalent to 91.8 receivable days. The read on the result depends heavily on whether this is a milk-cycle timing effect or a durable shift.

Payout ratio versus pre-lease FCF is suppressed because pre-lease FCF is negative.

Segment mix continues to rotate away from core genetics. The NZ market genetics segment, still 57.8% of revenue, contributed $65.0m of segment result, down from $68.5m on lower milk-price-driven volumes. Diagnostics (revenue +14.1%, segment result +39.7%) and Farm Software (revenue +3.4%, result +7.0%) grew on smaller bases. The diversifying segments are gaining share but are not yet large enough to offset genetics softness in absolute terms.

Against HY24 NPAT of $29.0m, this implies a material H2 loss of roughly $7-12m. That shape is consistent with the supplied seasonality: HY23 produced 121.8% of FY23 NPAT, so a loss-making second half is the normal pattern for LIC's mating-season-weighted business. The HY24 result is therefore not, on its face, inconsistent with full-year guidance — but it leaves no buffer if dairy-sector pressure widens further into the second half.

The release supplies no forward-work or order-book context, and no segment-level margin disclosure, so the durability of the FY24 guide rests on management commentary alone.

The 0.2pp gap between PBT and NPAT growth confirms tax is not masking anything, so the deterioration is real and is concentrated below the operating profit line in cash terms. With OCF at $3.4m and capex at $15.7m, the cash-flow picture is materially worse than the reported $29.0m profit; the difference is absorbed in working capital and a step-up in software and equipment spend.

Capex up 63.7%, split between $7.6m software development and $8.0m land/buildings/equipment, reflects ongoing R&D and platform investment that should be partially durable, but the timing concentration in H1 amplifies the FCF swing. The balance sheet remains a buffer — net cash of $38.3m, equity of $312.5m, zero borrowings, NTA of $1.92 per share — so distribution capacity is not in immediate question, but it is being drawn down rather than replenished by operations this half.

This briefing cannot assess management's working capital normalisation timeline or the sustainability of the dividend without disclosed H2 cash conversion expectations.